Exclusive Patent License for Catheter-Based Myotomy Devices
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This notice informs about a potential exclusive patent license grant to Septune, Inc. for catheter-based myotomy systems. These devices are designed to improve the treatment of cardiovascular diseases such as hypertrophic cardiomyopathy by enabling precise heart muscle incision. Companies in medical device manufacturing should consider its implications for new product development.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Potential grant of exclusive patent license to Septune, Inc.
- Focus on developing catheter-based myotomy systems for cardiovascular treatment
- Aims to reduce procedure complexity and improve outcomes for heart conditions
Obligations
What this law requires
Submit written comments and/or applications for a license to the NHLBI Office of Technology Transfer and Development by May 14, 2026 to be considered for objection or alternative licensing
Direct all requests for copies of patent applications, inquiries, and comments relating to the contemplated exclusive patent license to Michael Shmilovich, Esq., MS, CLP at phone 301-435-5019 or shmilovm@nih.gov
Demonstrate in writing within 30 days of notice publication that grant of exclusive license to Septune, Inc. would not be consistent with 35 U.S.C. 209 and 37 CFR part 404 requirements to prevent the exclusive license grant
Complete license applications filed in response to this notice will be treated as formal objections to the grant of the contemplated exclusive patent license to Septune, Inc.
Recognize that the exclusive patent license territory may be worldwide and limited to catheter-based myocardial myotomy systems for treatment of cardiovascular disease if granted to Septune, Inc.